Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG

Background: This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from October 2019 to January 2020. The primary endpoint was the incidence of influenza-like illness (ILI) until 30 April 2020. All the ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded. Therefore, the study prospectively recorded all the COVID-19 ILI events. Patients and methods: Patients were included in this non-prespecified COVID-19 analysis, if alive on 31 January 2020, when the Italian government declared the national emergency. The prevalence of confirmed COVID-19 cases was detected as ILI episode with laboratory confirmation of SARS-CoV-2. Cases with clinical-radiological diagnosis of COVID-19 (COVID-like ILIs), were also reported. Results: Out of 1257 enrolled patients, 955 matched the inclusion criteria for this unplanned analysis. From 31 January to 30 April 2020, 66 patients had ILI: 9 of 955 cases were confirmed COVID-19 ILIs, with prevalence of 0.9% [95% confidence interval (CI): 0.3–2.4], a hospitalization rate of 100% and a mortality rate of 77.8%. Including 5 COVID-like ILIs, the overall COVID-19 prevalence was 1.5% (95% CI: 0.5–3.1), with 100% hospitalization and 64% mortality. The presence of elderly, males and comorbidities was significantly higher among patients vaccinated against influenza versus unvaccinated ( p = 0.009, p < 0.0001, p < 0.0001). Overall COVID-19 prevalence was 1.2% for vaccinated (six of 482 cases, all confirmed) and 1.7% for unvaccinated (8 of 473, 3 confirmed COVID-19 and 5 COVID-like), p = 0.52. The difference remained non-significant, considering confirmed COVID-19 only ( p = 0.33). Conclusion: COVID-19 has a meaningful clinical impact on the cancer-patient population receiving ICIs, with high prevalence, hospitalization and an alarming mortality rate among symptomatic cases. Influenza vaccination does not protect from SARS-CoV-2 infection. Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Melissa Bersanelli [verfasserIn] Diana Giannarelli [verfasserIn] Ugo De Giorgi [verfasserIn] Sandro Pignata [verfasserIn] Massimo Di Maio [verfasserIn] Elena Verzoni [verfasserIn] Alberto Clemente [verfasserIn] Valentina Guadalupi [verfasserIn] Diego Signorelli [verfasserIn] Marcello Tiseo [verfasserIn] Raffaele Giusti [verfasserIn] Marco Filetti [verfasserIn] Marilena Di Napoli [verfasserIn] Lorenzo Calvetti [verfasserIn] Alessandro Cappetta [verfasserIn] Paola Ermacora [verfasserIn] Diego Zara [verfasserIn] Fausto Barbieri [verfasserIn] Cinzia Baldessari [verfasserIn] Vieri Scotti [verfasserIn] Francesca Mazzoni [verfasserIn] Antonello Veccia [verfasserIn] Pamela Francesca Guglielmini [verfasserIn] Marco Maruzzo [verfasserIn] Ernesto Rossi [verfasserIn] Francesco Grossi [verfasserIn] Chiara Casadei [verfasserIn] Alessio Cortellini [verfasserIn] Francesco Verderame [verfasserIn] Vincenzo Montesarchio [verfasserIn] Mimma Rizzo [verfasserIn] Manlio Mencoboni [verfasserIn] Fable Zustovich [verfasserIn] Lucia Fratino [verfasserIn] Saverio Cinieri [verfasserIn] Giorgia Negrini [verfasserIn] Maria Banzi [verfasserIn] Mariella Sorarù [verfasserIn] Paolo Andrea Zucali [verfasserIn] Gaetano Lacidogna [verfasserIn] Antonio Russo [verfasserIn] Nicola Battelli [verfasserIn] Giuseppe Fornarini [verfasserIn] Claudia Mucciarini [verfasserIn] Sergio Bracarda [verfasserIn] Andrea Bonetti [verfasserIn] Debora Pezzuolo [verfasserIn] Lucia Longo [verfasserIn] Donata Sartori [verfasserIn] Mauro Iannopollo [verfasserIn] Luigi Cavanna [verfasserIn] Fausto Meriggi [verfasserIn] Davide Tassinari [verfasserIn] Claudia Corbo [verfasserIn] Angela Gernone [verfasserIn] Veronica Prati [verfasserIn] Simona Carnio [verfasserIn] Pasqualina Giordano [verfasserIn] Angela Maria Dicorato [verfasserIn] Claudio Verusio [verfasserIn] Francesco Atzori [verfasserIn] Francesco Carrozza [verfasserIn] Stefania Gori [verfasserIn] Antonino Castro [verfasserIn] Sara Pilotto [verfasserIn] Vanja Vaccaro [verfasserIn] Elisabetta Garzoli [verfasserIn] Francesco Di Costanzo [verfasserIn] Evaristo Maiello [verfasserIn] Roberto Labianca [verfasserIn] Carmine Pinto [verfasserIn] Michele Tognetto [verfasserIn] Sebastiano Buti [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2020

Übergeordnetes Werk:	In: Therapeutic Advances in Medical Oncology - SAGE Publishing, 2018, 12(2020)
Übergeordnetes Werk:	volume:12 ; year:2020

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.1177/1758835920968463

Katalog-ID:	DOAJ048233021

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ048233021
003	DE-627
005	20230308133408.0
007	cr uuu---uuuuu
008	230227s2020 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1177/1758835920968463 \|2 doi
035			\|a (DE-627)DOAJ048233021
035			\|a (DE-599)DOAJ56f65524e4484c51b38e78016965cac1
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC254-282
100	0		\|a Melissa Bersanelli \|e verfasserin \|4 aut
245	1	0	\|a Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Background: This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from October 2019 to January 2020. The primary endpoint was the incidence of influenza-like illness (ILI) until 30 April 2020. All the ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded. Therefore, the study prospectively recorded all the COVID-19 ILI events. Patients and methods: Patients were included in this non-prespecified COVID-19 analysis, if alive on 31 January 2020, when the Italian government declared the national emergency. The prevalence of confirmed COVID-19 cases was detected as ILI episode with laboratory confirmation of SARS-CoV-2. Cases with clinical-radiological diagnosis of COVID-19 (COVID-like ILIs), were also reported. Results: Out of 1257 enrolled patients, 955 matched the inclusion criteria for this unplanned analysis. From 31 January to 30 April 2020, 66 patients had ILI: 9 of 955 cases were confirmed COVID-19 ILIs, with prevalence of 0.9% [95% confidence interval (CI): 0.3–2.4], a hospitalization rate of 100% and a mortality rate of 77.8%. Including 5 COVID-like ILIs, the overall COVID-19 prevalence was 1.5% (95% CI: 0.5–3.1), with 100% hospitalization and 64% mortality. The presence of elderly, males and comorbidities was significantly higher among patients vaccinated against influenza versus unvaccinated ( p = 0.009, p < 0.0001, p < 0.0001). Overall COVID-19 prevalence was 1.2% for vaccinated (six of 482 cases, all confirmed) and 1.7% for unvaccinated (8 of 473, 3 confirmed COVID-19 and 5 COVID-like), p = 0.52. The difference remained non-significant, considering confirmed COVID-19 only ( p = 0.33). Conclusion: COVID-19 has a meaningful clinical impact on the cancer-patient population receiving ICIs, with high prevalence, hospitalization and an alarming mortality rate among symptomatic cases. Influenza vaccination does not protect from SARS-CoV-2 infection.
653		0	\|a Neoplasms. Tumors. Oncology. Including cancer and carcinogens
700	0		\|a Diana Giannarelli \|e verfasserin \|4 aut
700	0		\|a Ugo De Giorgi \|e verfasserin \|4 aut
700	0		\|a Sandro Pignata \|e verfasserin \|4 aut
700	0		\|a Massimo Di Maio \|e verfasserin \|4 aut
700	0		\|a Elena Verzoni \|e verfasserin \|4 aut
700	0		\|a Alberto Clemente \|e verfasserin \|4 aut
700	0		\|a Valentina Guadalupi \|e verfasserin \|4 aut
700	0		\|a Diego Signorelli \|e verfasserin \|4 aut
700	0		\|a Marcello Tiseo \|e verfasserin \|4 aut
700	0		\|a Raffaele Giusti \|e verfasserin \|4 aut
700	0		\|a Marco Filetti \|e verfasserin \|4 aut
700	0		\|a Marilena Di Napoli \|e verfasserin \|4 aut
700	0		\|a Lorenzo Calvetti \|e verfasserin \|4 aut
700	0		\|a Alessandro Cappetta \|e verfasserin \|4 aut
700	0		\|a Paola Ermacora \|e verfasserin \|4 aut
700	0		\|a Diego Zara \|e verfasserin \|4 aut
700	0		\|a Fausto Barbieri \|e verfasserin \|4 aut
700	0		\|a Cinzia Baldessari \|e verfasserin \|4 aut
700	0		\|a Vieri Scotti \|e verfasserin \|4 aut
700	0		\|a Francesca Mazzoni \|e verfasserin \|4 aut
700	0		\|a Antonello Veccia \|e verfasserin \|4 aut
700	0		\|a Pamela Francesca Guglielmini \|e verfasserin \|4 aut
700	0		\|a Marco Maruzzo \|e verfasserin \|4 aut
700	0		\|a Ernesto Rossi \|e verfasserin \|4 aut
700	0		\|a Francesco Grossi \|e verfasserin \|4 aut
700	0		\|a Chiara Casadei \|e verfasserin \|4 aut
700	0		\|a Alessio Cortellini \|e verfasserin \|4 aut
700	0		\|a Francesco Verderame \|e verfasserin \|4 aut
700	0		\|a Vincenzo Montesarchio \|e verfasserin \|4 aut
700	0		\|a Mimma Rizzo \|e verfasserin \|4 aut
700	0		\|a Manlio Mencoboni \|e verfasserin \|4 aut
700	0		\|a Fable Zustovich \|e verfasserin \|4 aut
700	0		\|a Lucia Fratino \|e verfasserin \|4 aut
700	0		\|a Saverio Cinieri \|e verfasserin \|4 aut
700	0		\|a Giorgia Negrini \|e verfasserin \|4 aut
700	0		\|a Maria Banzi \|e verfasserin \|4 aut
700	0		\|a Mariella Sorarù \|e verfasserin \|4 aut
700	0		\|a Paolo Andrea Zucali \|e verfasserin \|4 aut
700	0		\|a Gaetano Lacidogna \|e verfasserin \|4 aut
700	0		\|a Antonio Russo \|e verfasserin \|4 aut
700	0		\|a Nicola Battelli \|e verfasserin \|4 aut
700	0		\|a Giuseppe Fornarini \|e verfasserin \|4 aut
700	0		\|a Claudia Mucciarini \|e verfasserin \|4 aut
700	0		\|a Sergio Bracarda \|e verfasserin \|4 aut
700	0		\|a Andrea Bonetti \|e verfasserin \|4 aut
700	0		\|a Debora Pezzuolo \|e verfasserin \|4 aut
700	0		\|a Lucia Longo \|e verfasserin \|4 aut
700	0		\|a Donata Sartori \|e verfasserin \|4 aut
700	0		\|a Mauro Iannopollo \|e verfasserin \|4 aut
700	0		\|a Luigi Cavanna \|e verfasserin \|4 aut
700	0		\|a Fausto Meriggi \|e verfasserin \|4 aut
700	0		\|a Davide Tassinari \|e verfasserin \|4 aut
700	0		\|a Claudia Corbo \|e verfasserin \|4 aut
700	0		\|a Angela Gernone \|e verfasserin \|4 aut
700	0		\|a Veronica Prati \|e verfasserin \|4 aut
700	0		\|a Simona Carnio \|e verfasserin \|4 aut
700	0		\|a Pasqualina Giordano \|e verfasserin \|4 aut
700	0		\|a Angela Maria Dicorato \|e verfasserin \|4 aut
700	0		\|a Claudio Verusio \|e verfasserin \|4 aut
700	0		\|a Francesco Atzori \|e verfasserin \|4 aut
700	0		\|a Francesco Carrozza \|e verfasserin \|4 aut
700	0		\|a Stefania Gori \|e verfasserin \|4 aut
700	0		\|a Antonino Castro \|e verfasserin \|4 aut
700	0		\|a Sara Pilotto \|e verfasserin \|4 aut
700	0		\|a Vanja Vaccaro \|e verfasserin \|4 aut
700	0		\|a Elisabetta Garzoli \|e verfasserin \|4 aut
700	0		\|a Francesco Di Costanzo \|e verfasserin \|4 aut
700	0		\|a Evaristo Maiello \|e verfasserin \|4 aut
700	0		\|a Roberto Labianca \|e verfasserin \|4 aut
700	0		\|a Carmine Pinto \|e verfasserin \|4 aut
700	0		\|a Michele Tognetto \|e verfasserin \|4 aut
700	0		\|a Sebastiano Buti \|e verfasserin \|4 aut
773	0	8	\|i In \|t Therapeutic Advances in Medical Oncology \|d SAGE Publishing, 2018 \|g 12(2020) \|w (DE-627)604082282 \|w (DE-600)2503443-1 \|x 17588359 \|7 nnns
773	1	8	\|g volume:12 \|g year:2020
856	4	0	\|u https://doi.org/10.1177/1758835920968463 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/56f65524e4484c51b38e78016965cac1 \|z kostenfrei
856	4	0	\|u https://doi.org/10.1177/1758835920968463 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1758-8359 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_121
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_374
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2704
912			\|a GBV_ILN_2707
912			\|a GBV_ILN_2889
912			\|a GBV_ILN_2890
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 12 \|j 2020

Indexfelder

author_variant	m b mb d g dg u d g udg s p sp m d m mdm e v ev a c ac v g vg d s ds m t mt r g rg m f mf m d n mdn l c lc a c ac p e pe d z dz f b fb c b cb v s vs f m fm a v av p f g pfg m m mm e r er f g fg c c cc a c ac f v fv v m vm m r mr m m mm f z fz l f lf s c sc g n gn m b mb m s ms p a z paz g l gl a r ar n b nb g f gf c m cm s b sb a b ab d p dp l l ll d s ds m i mi l c lc f m fm d t dt c c cc a g ag v p vp s c sc p g pg a m d amd c v cv f a fa f c fc s g sg a c ac s p sp v v vv e g eg f d c fdc e m em r l rl c p cp m t mt s b sb
matchkey_str	article:17588359:2020----::ypoaicvd9ndacdacrainsraewtimncekonihbtrpopcienlssrm
hierarchy_sort_str	2020
callnumber-subject-code	RC
publishDate	2020
allfields	10.1177/1758835920968463 doi (DE-627)DOAJ048233021 (DE-599)DOAJ56f65524e4484c51b38e78016965cac1 DE-627 ger DE-627 rakwb eng RC254-282 Melissa Bersanelli verfasserin aut Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from October 2019 to January 2020. The primary endpoint was the incidence of influenza-like illness (ILI) until 30 April 2020. All the ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded. Therefore, the study prospectively recorded all the COVID-19 ILI events. Patients and methods: Patients were included in this non-prespecified COVID-19 analysis, if alive on 31 January 2020, when the Italian government declared the national emergency. The prevalence of confirmed COVID-19 cases was detected as ILI episode with laboratory confirmation of SARS-CoV-2. Cases with clinical-radiological diagnosis of COVID-19 (COVID-like ILIs), were also reported. Results: Out of 1257 enrolled patients, 955 matched the inclusion criteria for this unplanned analysis. From 31 January to 30 April 2020, 66 patients had ILI: 9 of 955 cases were confirmed COVID-19 ILIs, with prevalence of 0.9% [95% confidence interval (CI): 0.3–2.4], a hospitalization rate of 100% and a mortality rate of 77.8%. Including 5 COVID-like ILIs, the overall COVID-19 prevalence was 1.5% (95% CI: 0.5–3.1), with 100% hospitalization and 64% mortality. The presence of elderly, males and comorbidities was significantly higher among patients vaccinated against influenza versus unvaccinated ( p = 0.009, p < 0.0001, p < 0.0001). Overall COVID-19 prevalence was 1.2% for vaccinated (six of 482 cases, all confirmed) and 1.7% for unvaccinated (8 of 473, 3 confirmed COVID-19 and 5 COVID-like), p = 0.52. The difference remained non-significant, considering confirmed COVID-19 only ( p = 0.33). Conclusion: COVID-19 has a meaningful clinical impact on the cancer-patient population receiving ICIs, with high prevalence, hospitalization and an alarming mortality rate among symptomatic cases. Influenza vaccination does not protect from SARS-CoV-2 infection. Neoplasms. Tumors. Oncology. Including cancer and carcinogens Diana Giannarelli verfasserin aut Ugo De Giorgi verfasserin aut Sandro Pignata verfasserin aut Massimo Di Maio verfasserin aut Elena Verzoni verfasserin aut Alberto Clemente verfasserin aut Valentina Guadalupi verfasserin aut Diego Signorelli verfasserin aut Marcello Tiseo verfasserin aut Raffaele Giusti verfasserin aut Marco Filetti verfasserin aut Marilena Di Napoli verfasserin aut Lorenzo Calvetti verfasserin aut Alessandro Cappetta verfasserin aut Paola Ermacora verfasserin aut Diego Zara verfasserin aut Fausto Barbieri verfasserin aut Cinzia Baldessari verfasserin aut Vieri Scotti verfasserin aut Francesca Mazzoni verfasserin aut Antonello Veccia verfasserin aut Pamela Francesca Guglielmini verfasserin aut Marco Maruzzo verfasserin aut Ernesto Rossi verfasserin aut Francesco Grossi verfasserin aut Chiara Casadei verfasserin aut Alessio Cortellini verfasserin aut Francesco Verderame verfasserin aut Vincenzo Montesarchio verfasserin aut Mimma Rizzo verfasserin aut Manlio Mencoboni verfasserin aut Fable Zustovich verfasserin aut Lucia Fratino verfasserin aut Saverio Cinieri verfasserin aut Giorgia Negrini verfasserin aut Maria Banzi verfasserin aut Mariella Sorarù verfasserin aut Paolo Andrea Zucali verfasserin aut Gaetano Lacidogna verfasserin aut Antonio Russo verfasserin aut Nicola Battelli verfasserin aut Giuseppe Fornarini verfasserin aut Claudia Mucciarini verfasserin aut Sergio Bracarda verfasserin aut Andrea Bonetti verfasserin aut Debora Pezzuolo verfasserin aut Lucia Longo verfasserin aut Donata Sartori verfasserin aut Mauro Iannopollo verfasserin aut Luigi Cavanna verfasserin aut Fausto Meriggi verfasserin aut Davide Tassinari verfasserin aut Claudia Corbo verfasserin aut Angela Gernone verfasserin aut Veronica Prati verfasserin aut Simona Carnio verfasserin aut Pasqualina Giordano verfasserin aut Angela Maria Dicorato verfasserin aut Claudio Verusio verfasserin aut Francesco Atzori verfasserin aut Francesco Carrozza verfasserin aut Stefania Gori verfasserin aut Antonino Castro verfasserin aut Sara Pilotto verfasserin aut Vanja Vaccaro verfasserin aut Elisabetta Garzoli verfasserin aut Francesco Di Costanzo verfasserin aut Evaristo Maiello verfasserin aut Roberto Labianca verfasserin aut Carmine Pinto verfasserin aut Michele Tognetto verfasserin aut Sebastiano Buti verfasserin aut In Therapeutic Advances in Medical Oncology SAGE Publishing, 2018 12(2020) (DE-627)604082282 (DE-600)2503443-1 17588359 nnns volume:12 year:2020 https://doi.org/10.1177/1758835920968463 kostenfrei https://doaj.org/article/56f65524e4484c51b38e78016965cac1 kostenfrei https://doi.org/10.1177/1758835920968463 kostenfrei https://doaj.org/toc/1758-8359 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_121 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_374 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2704 GBV_ILN_2707 GBV_ILN_2889 GBV_ILN_2890 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2020
spelling	10.1177/1758835920968463 doi (DE-627)DOAJ048233021 (DE-599)DOAJ56f65524e4484c51b38e78016965cac1 DE-627 ger DE-627 rakwb eng RC254-282 Melissa Bersanelli verfasserin aut Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from October 2019 to January 2020. The primary endpoint was the incidence of influenza-like illness (ILI) until 30 April 2020. All the ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded. Therefore, the study prospectively recorded all the COVID-19 ILI events. Patients and methods: Patients were included in this non-prespecified COVID-19 analysis, if alive on 31 January 2020, when the Italian government declared the national emergency. The prevalence of confirmed COVID-19 cases was detected as ILI episode with laboratory confirmation of SARS-CoV-2. Cases with clinical-radiological diagnosis of COVID-19 (COVID-like ILIs), were also reported. Results: Out of 1257 enrolled patients, 955 matched the inclusion criteria for this unplanned analysis. From 31 January to 30 April 2020, 66 patients had ILI: 9 of 955 cases were confirmed COVID-19 ILIs, with prevalence of 0.9% [95% confidence interval (CI): 0.3–2.4], a hospitalization rate of 100% and a mortality rate of 77.8%. Including 5 COVID-like ILIs, the overall COVID-19 prevalence was 1.5% (95% CI: 0.5–3.1), with 100% hospitalization and 64% mortality. The presence of elderly, males and comorbidities was significantly higher among patients vaccinated against influenza versus unvaccinated ( p = 0.009, p < 0.0001, p < 0.0001). Overall COVID-19 prevalence was 1.2% for vaccinated (six of 482 cases, all confirmed) and 1.7% for unvaccinated (8 of 473, 3 confirmed COVID-19 and 5 COVID-like), p = 0.52. The difference remained non-significant, considering confirmed COVID-19 only ( p = 0.33). Conclusion: COVID-19 has a meaningful clinical impact on the cancer-patient population receiving ICIs, with high prevalence, hospitalization and an alarming mortality rate among symptomatic cases. Influenza vaccination does not protect from SARS-CoV-2 infection. Neoplasms. Tumors. Oncology. Including cancer and carcinogens Diana Giannarelli verfasserin aut Ugo De Giorgi verfasserin aut Sandro Pignata verfasserin aut Massimo Di Maio verfasserin aut Elena Verzoni verfasserin aut Alberto Clemente verfasserin aut Valentina Guadalupi verfasserin aut Diego Signorelli verfasserin aut Marcello Tiseo verfasserin aut Raffaele Giusti verfasserin aut Marco Filetti verfasserin aut Marilena Di Napoli verfasserin aut Lorenzo Calvetti verfasserin aut Alessandro Cappetta verfasserin aut Paola Ermacora verfasserin aut Diego Zara verfasserin aut Fausto Barbieri verfasserin aut Cinzia Baldessari verfasserin aut Vieri Scotti verfasserin aut Francesca Mazzoni verfasserin aut Antonello Veccia verfasserin aut Pamela Francesca Guglielmini verfasserin aut Marco Maruzzo verfasserin aut Ernesto Rossi verfasserin aut Francesco Grossi verfasserin aut Chiara Casadei verfasserin aut Alessio Cortellini verfasserin aut Francesco Verderame verfasserin aut Vincenzo Montesarchio verfasserin aut Mimma Rizzo verfasserin aut Manlio Mencoboni verfasserin aut Fable Zustovich verfasserin aut Lucia Fratino verfasserin aut Saverio Cinieri verfasserin aut Giorgia Negrini verfasserin aut Maria Banzi verfasserin aut Mariella Sorarù verfasserin aut Paolo Andrea Zucali verfasserin aut Gaetano Lacidogna verfasserin aut Antonio Russo verfasserin aut Nicola Battelli verfasserin aut Giuseppe Fornarini verfasserin aut Claudia Mucciarini verfasserin aut Sergio Bracarda verfasserin aut Andrea Bonetti verfasserin aut Debora Pezzuolo verfasserin aut Lucia Longo verfasserin aut Donata Sartori verfasserin aut Mauro Iannopollo verfasserin aut Luigi Cavanna verfasserin aut Fausto Meriggi verfasserin aut Davide Tassinari verfasserin aut Claudia Corbo verfasserin aut Angela Gernone verfasserin aut Veronica Prati verfasserin aut Simona Carnio verfasserin aut Pasqualina Giordano verfasserin aut Angela Maria Dicorato verfasserin aut Claudio Verusio verfasserin aut Francesco Atzori verfasserin aut Francesco Carrozza verfasserin aut Stefania Gori verfasserin aut Antonino Castro verfasserin aut Sara Pilotto verfasserin aut Vanja Vaccaro verfasserin aut Elisabetta Garzoli verfasserin aut Francesco Di Costanzo verfasserin aut Evaristo Maiello verfasserin aut Roberto Labianca verfasserin aut Carmine Pinto verfasserin aut Michele Tognetto verfasserin aut Sebastiano Buti verfasserin aut In Therapeutic Advances in Medical Oncology SAGE Publishing, 2018 12(2020) (DE-627)604082282 (DE-600)2503443-1 17588359 nnns volume:12 year:2020 https://doi.org/10.1177/1758835920968463 kostenfrei https://doaj.org/article/56f65524e4484c51b38e78016965cac1 kostenfrei https://doi.org/10.1177/1758835920968463 kostenfrei https://doaj.org/toc/1758-8359 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_121 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_374 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2704 GBV_ILN_2707 GBV_ILN_2889 GBV_ILN_2890 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2020
allfields_unstemmed	10.1177/1758835920968463 doi (DE-627)DOAJ048233021 (DE-599)DOAJ56f65524e4484c51b38e78016965cac1 DE-627 ger DE-627 rakwb eng RC254-282 Melissa Bersanelli verfasserin aut Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from October 2019 to January 2020. The primary endpoint was the incidence of influenza-like illness (ILI) until 30 April 2020. All the ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded. Therefore, the study prospectively recorded all the COVID-19 ILI events. Patients and methods: Patients were included in this non-prespecified COVID-19 analysis, if alive on 31 January 2020, when the Italian government declared the national emergency. The prevalence of confirmed COVID-19 cases was detected as ILI episode with laboratory confirmation of SARS-CoV-2. Cases with clinical-radiological diagnosis of COVID-19 (COVID-like ILIs), were also reported. Results: Out of 1257 enrolled patients, 955 matched the inclusion criteria for this unplanned analysis. From 31 January to 30 April 2020, 66 patients had ILI: 9 of 955 cases were confirmed COVID-19 ILIs, with prevalence of 0.9% [95% confidence interval (CI): 0.3–2.4], a hospitalization rate of 100% and a mortality rate of 77.8%. Including 5 COVID-like ILIs, the overall COVID-19 prevalence was 1.5% (95% CI: 0.5–3.1), with 100% hospitalization and 64% mortality. The presence of elderly, males and comorbidities was significantly higher among patients vaccinated against influenza versus unvaccinated ( p = 0.009, p < 0.0001, p < 0.0001). Overall COVID-19 prevalence was 1.2% for vaccinated (six of 482 cases, all confirmed) and 1.7% for unvaccinated (8 of 473, 3 confirmed COVID-19 and 5 COVID-like), p = 0.52. The difference remained non-significant, considering confirmed COVID-19 only ( p = 0.33). Conclusion: COVID-19 has a meaningful clinical impact on the cancer-patient population receiving ICIs, with high prevalence, hospitalization and an alarming mortality rate among symptomatic cases. Influenza vaccination does not protect from SARS-CoV-2 infection. Neoplasms. Tumors. Oncology. Including cancer and carcinogens Diana Giannarelli verfasserin aut Ugo De Giorgi verfasserin aut Sandro Pignata verfasserin aut Massimo Di Maio verfasserin aut Elena Verzoni verfasserin aut Alberto Clemente verfasserin aut Valentina Guadalupi verfasserin aut Diego Signorelli verfasserin aut Marcello Tiseo verfasserin aut Raffaele Giusti verfasserin aut Marco Filetti verfasserin aut Marilena Di Napoli verfasserin aut Lorenzo Calvetti verfasserin aut Alessandro Cappetta verfasserin aut Paola Ermacora verfasserin aut Diego Zara verfasserin aut Fausto Barbieri verfasserin aut Cinzia Baldessari verfasserin aut Vieri Scotti verfasserin aut Francesca Mazzoni verfasserin aut Antonello Veccia verfasserin aut Pamela Francesca Guglielmini verfasserin aut Marco Maruzzo verfasserin aut Ernesto Rossi verfasserin aut Francesco Grossi verfasserin aut Chiara Casadei verfasserin aut Alessio Cortellini verfasserin aut Francesco Verderame verfasserin aut Vincenzo Montesarchio verfasserin aut Mimma Rizzo verfasserin aut Manlio Mencoboni verfasserin aut Fable Zustovich verfasserin aut Lucia Fratino verfasserin aut Saverio Cinieri verfasserin aut Giorgia Negrini verfasserin aut Maria Banzi verfasserin aut Mariella Sorarù verfasserin aut Paolo Andrea Zucali verfasserin aut Gaetano Lacidogna verfasserin aut Antonio Russo verfasserin aut Nicola Battelli verfasserin aut Giuseppe Fornarini verfasserin aut Claudia Mucciarini verfasserin aut Sergio Bracarda verfasserin aut Andrea Bonetti verfasserin aut Debora Pezzuolo verfasserin aut Lucia Longo verfasserin aut Donata Sartori verfasserin aut Mauro Iannopollo verfasserin aut Luigi Cavanna verfasserin aut Fausto Meriggi verfasserin aut Davide Tassinari verfasserin aut Claudia Corbo verfasserin aut Angela Gernone verfasserin aut Veronica Prati verfasserin aut Simona Carnio verfasserin aut Pasqualina Giordano verfasserin aut Angela Maria Dicorato verfasserin aut Claudio Verusio verfasserin aut Francesco Atzori verfasserin aut Francesco Carrozza verfasserin aut Stefania Gori verfasserin aut Antonino Castro verfasserin aut Sara Pilotto verfasserin aut Vanja Vaccaro verfasserin aut Elisabetta Garzoli verfasserin aut Francesco Di Costanzo verfasserin aut Evaristo Maiello verfasserin aut Roberto Labianca verfasserin aut Carmine Pinto verfasserin aut Michele Tognetto verfasserin aut Sebastiano Buti verfasserin aut In Therapeutic Advances in Medical Oncology SAGE Publishing, 2018 12(2020) (DE-627)604082282 (DE-600)2503443-1 17588359 nnns volume:12 year:2020 https://doi.org/10.1177/1758835920968463 kostenfrei https://doaj.org/article/56f65524e4484c51b38e78016965cac1 kostenfrei https://doi.org/10.1177/1758835920968463 kostenfrei https://doaj.org/toc/1758-8359 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_121 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_374 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2704 GBV_ILN_2707 GBV_ILN_2889 GBV_ILN_2890 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2020
allfieldsGer	10.1177/1758835920968463 doi (DE-627)DOAJ048233021 (DE-599)DOAJ56f65524e4484c51b38e78016965cac1 DE-627 ger DE-627 rakwb eng RC254-282 Melissa Bersanelli verfasserin aut Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from October 2019 to January 2020. The primary endpoint was the incidence of influenza-like illness (ILI) until 30 April 2020. All the ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded. Therefore, the study prospectively recorded all the COVID-19 ILI events. Patients and methods: Patients were included in this non-prespecified COVID-19 analysis, if alive on 31 January 2020, when the Italian government declared the national emergency. The prevalence of confirmed COVID-19 cases was detected as ILI episode with laboratory confirmation of SARS-CoV-2. Cases with clinical-radiological diagnosis of COVID-19 (COVID-like ILIs), were also reported. Results: Out of 1257 enrolled patients, 955 matched the inclusion criteria for this unplanned analysis. From 31 January to 30 April 2020, 66 patients had ILI: 9 of 955 cases were confirmed COVID-19 ILIs, with prevalence of 0.9% [95% confidence interval (CI): 0.3–2.4], a hospitalization rate of 100% and a mortality rate of 77.8%. Including 5 COVID-like ILIs, the overall COVID-19 prevalence was 1.5% (95% CI: 0.5–3.1), with 100% hospitalization and 64% mortality. The presence of elderly, males and comorbidities was significantly higher among patients vaccinated against influenza versus unvaccinated ( p = 0.009, p < 0.0001, p < 0.0001). Overall COVID-19 prevalence was 1.2% for vaccinated (six of 482 cases, all confirmed) and 1.7% for unvaccinated (8 of 473, 3 confirmed COVID-19 and 5 COVID-like), p = 0.52. The difference remained non-significant, considering confirmed COVID-19 only ( p = 0.33). Conclusion: COVID-19 has a meaningful clinical impact on the cancer-patient population receiving ICIs, with high prevalence, hospitalization and an alarming mortality rate among symptomatic cases. Influenza vaccination does not protect from SARS-CoV-2 infection. Neoplasms. Tumors. Oncology. Including cancer and carcinogens Diana Giannarelli verfasserin aut Ugo De Giorgi verfasserin aut Sandro Pignata verfasserin aut Massimo Di Maio verfasserin aut Elena Verzoni verfasserin aut Alberto Clemente verfasserin aut Valentina Guadalupi verfasserin aut Diego Signorelli verfasserin aut Marcello Tiseo verfasserin aut Raffaele Giusti verfasserin aut Marco Filetti verfasserin aut Marilena Di Napoli verfasserin aut Lorenzo Calvetti verfasserin aut Alessandro Cappetta verfasserin aut Paola Ermacora verfasserin aut Diego Zara verfasserin aut Fausto Barbieri verfasserin aut Cinzia Baldessari verfasserin aut Vieri Scotti verfasserin aut Francesca Mazzoni verfasserin aut Antonello Veccia verfasserin aut Pamela Francesca Guglielmini verfasserin aut Marco Maruzzo verfasserin aut Ernesto Rossi verfasserin aut Francesco Grossi verfasserin aut Chiara Casadei verfasserin aut Alessio Cortellini verfasserin aut Francesco Verderame verfasserin aut Vincenzo Montesarchio verfasserin aut Mimma Rizzo verfasserin aut Manlio Mencoboni verfasserin aut Fable Zustovich verfasserin aut Lucia Fratino verfasserin aut Saverio Cinieri verfasserin aut Giorgia Negrini verfasserin aut Maria Banzi verfasserin aut Mariella Sorarù verfasserin aut Paolo Andrea Zucali verfasserin aut Gaetano Lacidogna verfasserin aut Antonio Russo verfasserin aut Nicola Battelli verfasserin aut Giuseppe Fornarini verfasserin aut Claudia Mucciarini verfasserin aut Sergio Bracarda verfasserin aut Andrea Bonetti verfasserin aut Debora Pezzuolo verfasserin aut Lucia Longo verfasserin aut Donata Sartori verfasserin aut Mauro Iannopollo verfasserin aut Luigi Cavanna verfasserin aut Fausto Meriggi verfasserin aut Davide Tassinari verfasserin aut Claudia Corbo verfasserin aut Angela Gernone verfasserin aut Veronica Prati verfasserin aut Simona Carnio verfasserin aut Pasqualina Giordano verfasserin aut Angela Maria Dicorato verfasserin aut Claudio Verusio verfasserin aut Francesco Atzori verfasserin aut Francesco Carrozza verfasserin aut Stefania Gori verfasserin aut Antonino Castro verfasserin aut Sara Pilotto verfasserin aut Vanja Vaccaro verfasserin aut Elisabetta Garzoli verfasserin aut Francesco Di Costanzo verfasserin aut Evaristo Maiello verfasserin aut Roberto Labianca verfasserin aut Carmine Pinto verfasserin aut Michele Tognetto verfasserin aut Sebastiano Buti verfasserin aut In Therapeutic Advances in Medical Oncology SAGE Publishing, 2018 12(2020) (DE-627)604082282 (DE-600)2503443-1 17588359 nnns volume:12 year:2020 https://doi.org/10.1177/1758835920968463 kostenfrei https://doaj.org/article/56f65524e4484c51b38e78016965cac1 kostenfrei https://doi.org/10.1177/1758835920968463 kostenfrei https://doaj.org/toc/1758-8359 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_121 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_374 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2704 GBV_ILN_2707 GBV_ILN_2889 GBV_ILN_2890 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2020
allfieldsSound	10.1177/1758835920968463 doi (DE-627)DOAJ048233021 (DE-599)DOAJ56f65524e4484c51b38e78016965cac1 DE-627 ger DE-627 rakwb eng RC254-282 Melissa Bersanelli verfasserin aut Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from October 2019 to January 2020. The primary endpoint was the incidence of influenza-like illness (ILI) until 30 April 2020. All the ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded. Therefore, the study prospectively recorded all the COVID-19 ILI events. Patients and methods: Patients were included in this non-prespecified COVID-19 analysis, if alive on 31 January 2020, when the Italian government declared the national emergency. The prevalence of confirmed COVID-19 cases was detected as ILI episode with laboratory confirmation of SARS-CoV-2. Cases with clinical-radiological diagnosis of COVID-19 (COVID-like ILIs), were also reported. Results: Out of 1257 enrolled patients, 955 matched the inclusion criteria for this unplanned analysis. From 31 January to 30 April 2020, 66 patients had ILI: 9 of 955 cases were confirmed COVID-19 ILIs, with prevalence of 0.9% [95% confidence interval (CI): 0.3–2.4], a hospitalization rate of 100% and a mortality rate of 77.8%. Including 5 COVID-like ILIs, the overall COVID-19 prevalence was 1.5% (95% CI: 0.5–3.1), with 100% hospitalization and 64% mortality. The presence of elderly, males and comorbidities was significantly higher among patients vaccinated against influenza versus unvaccinated ( p = 0.009, p < 0.0001, p < 0.0001). Overall COVID-19 prevalence was 1.2% for vaccinated (six of 482 cases, all confirmed) and 1.7% for unvaccinated (8 of 473, 3 confirmed COVID-19 and 5 COVID-like), p = 0.52. The difference remained non-significant, considering confirmed COVID-19 only ( p = 0.33). Conclusion: COVID-19 has a meaningful clinical impact on the cancer-patient population receiving ICIs, with high prevalence, hospitalization and an alarming mortality rate among symptomatic cases. Influenza vaccination does not protect from SARS-CoV-2 infection. Neoplasms. Tumors. Oncology. Including cancer and carcinogens Diana Giannarelli verfasserin aut Ugo De Giorgi verfasserin aut Sandro Pignata verfasserin aut Massimo Di Maio verfasserin aut Elena Verzoni verfasserin aut Alberto Clemente verfasserin aut Valentina Guadalupi verfasserin aut Diego Signorelli verfasserin aut Marcello Tiseo verfasserin aut Raffaele Giusti verfasserin aut Marco Filetti verfasserin aut Marilena Di Napoli verfasserin aut Lorenzo Calvetti verfasserin aut Alessandro Cappetta verfasserin aut Paola Ermacora verfasserin aut Diego Zara verfasserin aut Fausto Barbieri verfasserin aut Cinzia Baldessari verfasserin aut Vieri Scotti verfasserin aut Francesca Mazzoni verfasserin aut Antonello Veccia verfasserin aut Pamela Francesca Guglielmini verfasserin aut Marco Maruzzo verfasserin aut Ernesto Rossi verfasserin aut Francesco Grossi verfasserin aut Chiara Casadei verfasserin aut Alessio Cortellini verfasserin aut Francesco Verderame verfasserin aut Vincenzo Montesarchio verfasserin aut Mimma Rizzo verfasserin aut Manlio Mencoboni verfasserin aut Fable Zustovich verfasserin aut Lucia Fratino verfasserin aut Saverio Cinieri verfasserin aut Giorgia Negrini verfasserin aut Maria Banzi verfasserin aut Mariella Sorarù verfasserin aut Paolo Andrea Zucali verfasserin aut Gaetano Lacidogna verfasserin aut Antonio Russo verfasserin aut Nicola Battelli verfasserin aut Giuseppe Fornarini verfasserin aut Claudia Mucciarini verfasserin aut Sergio Bracarda verfasserin aut Andrea Bonetti verfasserin aut Debora Pezzuolo verfasserin aut Lucia Longo verfasserin aut Donata Sartori verfasserin aut Mauro Iannopollo verfasserin aut Luigi Cavanna verfasserin aut Fausto Meriggi verfasserin aut Davide Tassinari verfasserin aut Claudia Corbo verfasserin aut Angela Gernone verfasserin aut Veronica Prati verfasserin aut Simona Carnio verfasserin aut Pasqualina Giordano verfasserin aut Angela Maria Dicorato verfasserin aut Claudio Verusio verfasserin aut Francesco Atzori verfasserin aut Francesco Carrozza verfasserin aut Stefania Gori verfasserin aut Antonino Castro verfasserin aut Sara Pilotto verfasserin aut Vanja Vaccaro verfasserin aut Elisabetta Garzoli verfasserin aut Francesco Di Costanzo verfasserin aut Evaristo Maiello verfasserin aut Roberto Labianca verfasserin aut Carmine Pinto verfasserin aut Michele Tognetto verfasserin aut Sebastiano Buti verfasserin aut In Therapeutic Advances in Medical Oncology SAGE Publishing, 2018 12(2020) (DE-627)604082282 (DE-600)2503443-1 17588359 nnns volume:12 year:2020 https://doi.org/10.1177/1758835920968463 kostenfrei https://doaj.org/article/56f65524e4484c51b38e78016965cac1 kostenfrei https://doi.org/10.1177/1758835920968463 kostenfrei https://doaj.org/toc/1758-8359 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_121 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_374 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2704 GBV_ILN_2707 GBV_ILN_2889 GBV_ILN_2890 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2020
language	English
source	In Therapeutic Advances in Medical Oncology 12(2020) volume:12 year:2020
sourceStr	In Therapeutic Advances in Medical Oncology 12(2020) volume:12 year:2020
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Neoplasms. Tumors. Oncology. Including cancer and carcinogens
isfreeaccess_bool	true
container_title	Therapeutic Advances in Medical Oncology
authorswithroles_txt_mv	Melissa Bersanelli @@aut@@ Diana Giannarelli @@aut@@ Ugo De Giorgi @@aut@@ Sandro Pignata @@aut@@ Massimo Di Maio @@aut@@ Elena Verzoni @@aut@@ Alberto Clemente @@aut@@ Valentina Guadalupi @@aut@@ Diego Signorelli @@aut@@ Marcello Tiseo @@aut@@ Raffaele Giusti @@aut@@ Marco Filetti @@aut@@ Marilena Di Napoli @@aut@@ Lorenzo Calvetti @@aut@@ Alessandro Cappetta @@aut@@ Paola Ermacora @@aut@@ Diego Zara @@aut@@ Fausto Barbieri @@aut@@ Cinzia Baldessari @@aut@@ Vieri Scotti @@aut@@ Francesca Mazzoni @@aut@@ Antonello Veccia @@aut@@ Pamela Francesca Guglielmini @@aut@@ Marco Maruzzo @@aut@@ Ernesto Rossi @@aut@@ Francesco Grossi @@aut@@ Chiara Casadei @@aut@@ Alessio Cortellini @@aut@@ Francesco Verderame @@aut@@ Vincenzo Montesarchio @@aut@@ Mimma Rizzo @@aut@@ Manlio Mencoboni @@aut@@ Fable Zustovich @@aut@@ Lucia Fratino @@aut@@ Saverio Cinieri @@aut@@ Giorgia Negrini @@aut@@ Maria Banzi @@aut@@ Mariella Sorarù @@aut@@ Paolo Andrea Zucali @@aut@@ Gaetano Lacidogna @@aut@@ Antonio Russo @@aut@@ Nicola Battelli @@aut@@ Giuseppe Fornarini @@aut@@ Claudia Mucciarini @@aut@@ Sergio Bracarda @@aut@@ Andrea Bonetti @@aut@@ Debora Pezzuolo @@aut@@ Lucia Longo @@aut@@ Donata Sartori @@aut@@ Mauro Iannopollo @@aut@@ Luigi Cavanna @@aut@@ Fausto Meriggi @@aut@@ Davide Tassinari @@aut@@ Claudia Corbo @@aut@@ Angela Gernone @@aut@@ Veronica Prati @@aut@@ Simona Carnio @@aut@@ Pasqualina Giordano @@aut@@ Angela Maria Dicorato @@aut@@ Claudio Verusio @@aut@@ Francesco Atzori @@aut@@ Francesco Carrozza @@aut@@ Stefania Gori @@aut@@ Antonino Castro @@aut@@ Sara Pilotto @@aut@@ Vanja Vaccaro @@aut@@ Elisabetta Garzoli @@aut@@ Francesco Di Costanzo @@aut@@ Evaristo Maiello @@aut@@ Roberto Labianca @@aut@@ Carmine Pinto @@aut@@ Michele Tognetto @@aut@@ Sebastiano Buti @@aut@@
publishDateDaySort_date	2020-01-01T00:00:00Z
hierarchy_top_id	604082282
id	DOAJ048233021
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ048233021</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308133408.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1177/1758835920968463</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ048233021</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ56f65524e4484c51b38e78016965cac1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Melissa Bersanelli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from October 2019 to January 2020. The primary endpoint was the incidence of influenza-like illness (ILI) until 30 April 2020. All the ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded. Therefore, the study prospectively recorded all the COVID-19 ILI events. Patients and methods: Patients were included in this non-prespecified COVID-19 analysis, if alive on 31 January 2020, when the Italian government declared the national emergency. The prevalence of confirmed COVID-19 cases was detected as ILI episode with laboratory confirmation of SARS-CoV-2. Cases with clinical-radiological diagnosis of COVID-19 (COVID-like ILIs), were also reported. Results: Out of 1257 enrolled patients, 955 matched the inclusion criteria for this unplanned analysis. From 31 January to 30 April 2020, 66 patients had ILI: 9 of 955 cases were confirmed COVID-19 ILIs, with prevalence of 0.9% [95% confidence interval (CI): 0.3–2.4], a hospitalization rate of 100% and a mortality rate of 77.8%. Including 5 COVID-like ILIs, the overall COVID-19 prevalence was 1.5% (95% CI: 0.5–3.1), with 100% hospitalization and 64% mortality. The presence of elderly, males and comorbidities was significantly higher among patients vaccinated against influenza versus unvaccinated ( p = 0.009, p < 0.0001, p < 0.0001). Overall COVID-19 prevalence was 1.2% for vaccinated (six of 482 cases, all confirmed) and 1.7% for unvaccinated (8 of 473, 3 confirmed COVID-19 and 5 COVID-like), p = 0.52. The difference remained non-significant, considering confirmed COVID-19 only ( p = 0.33). Conclusion: COVID-19 has a meaningful clinical impact on the cancer-patient population receiving ICIs, with high prevalence, hospitalization and an alarming mortality rate among symptomatic cases. Influenza vaccination does not protect from SARS-CoV-2 infection.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Diana Giannarelli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ugo De Giorgi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sandro Pignata</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Massimo Di Maio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Elena Verzoni</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alberto Clemente</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Valentina Guadalupi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Diego Signorelli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marcello Tiseo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Raffaele Giusti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marco Filetti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marilena Di Napoli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lorenzo Calvetti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alessandro Cappetta</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paola Ermacora</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Diego Zara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fausto Barbieri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cinzia Baldessari</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vieri Scotti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francesca Mazzoni</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Antonello Veccia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pamela Francesca Guglielmini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marco Maruzzo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ernesto Rossi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francesco Grossi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chiara Casadei</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alessio Cortellini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francesco Verderame</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vincenzo Montesarchio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mimma Rizzo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Manlio Mencoboni</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fable Zustovich</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lucia Fratino</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Saverio Cinieri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giorgia Negrini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maria Banzi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mariella Sorarù</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paolo Andrea Zucali</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gaetano Lacidogna</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Antonio Russo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicola Battelli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giuseppe Fornarini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Claudia Mucciarini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sergio Bracarda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrea Bonetti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Debora Pezzuolo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lucia Longo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Donata Sartori</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mauro Iannopollo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luigi Cavanna</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fausto Meriggi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Davide Tassinari</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Claudia Corbo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Angela Gernone</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Veronica Prati</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Simona Carnio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pasqualina Giordano</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Angela Maria Dicorato</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Claudio Verusio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francesco Atzori</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francesco Carrozza</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stefania Gori</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Antonino Castro</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sara Pilotto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vanja Vaccaro</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Elisabetta Garzoli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francesco Di Costanzo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Evaristo Maiello</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Roberto Labianca</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Carmine Pinto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Michele Tognetto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sebastiano Buti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Therapeutic Advances in Medical Oncology</subfield><subfield code="d">SAGE Publishing, 2018</subfield><subfield code="g">12(2020)</subfield><subfield code="w">(DE-627)604082282</subfield><subfield code="w">(DE-600)2503443-1</subfield><subfield code="x">17588359</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2020</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1177/1758835920968463</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/56f65524e4484c51b38e78016965cac1</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1177/1758835920968463</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1758-8359</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_121</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_374</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2704</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2707</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2889</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2890</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2020</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Melissa Bersanelli
spellingShingle	Melissa Bersanelli misc RC254-282 misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG
authorStr	Melissa Bersanelli
ppnlink_with_tag_str_mv	@@773@@(DE-627)604082282
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC254-282
illustrated	Not Illustrated
issn	17588359
topic_title	RC254-282 Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG
topic	misc RC254-282 misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_unstemmed	misc RC254-282 misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_browse	misc RC254-282 misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Therapeutic Advances in Medical Oncology
hierarchy_parent_id	604082282
hierarchy_top_title	Therapeutic Advances in Medical Oncology
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)604082282 (DE-600)2503443-1
title	Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG
ctrlnum	(DE-627)DOAJ048233021 (DE-599)DOAJ56f65524e4484c51b38e78016965cac1
title_full	Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG
author_sort	Melissa Bersanelli
journal	Therapeutic Advances in Medical Oncology
journalStr	Therapeutic Advances in Medical Oncology
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2020
contenttype_str_mv	txt
author_browse	Melissa Bersanelli Diana Giannarelli Ugo De Giorgi Sandro Pignata Massimo Di Maio Elena Verzoni Alberto Clemente Valentina Guadalupi Diego Signorelli Marcello Tiseo Raffaele Giusti Marco Filetti Marilena Di Napoli Lorenzo Calvetti Alessandro Cappetta Paola Ermacora Diego Zara Fausto Barbieri Cinzia Baldessari Vieri Scotti Francesca Mazzoni Antonello Veccia Pamela Francesca Guglielmini Marco Maruzzo Ernesto Rossi Francesco Grossi Chiara Casadei Alessio Cortellini Francesco Verderame Vincenzo Montesarchio Mimma Rizzo Manlio Mencoboni Fable Zustovich Lucia Fratino Saverio Cinieri Giorgia Negrini Maria Banzi Mariella Sorarù Paolo Andrea Zucali Gaetano Lacidogna Antonio Russo Nicola Battelli Giuseppe Fornarini Claudia Mucciarini Sergio Bracarda Andrea Bonetti Debora Pezzuolo Lucia Longo Donata Sartori Mauro Iannopollo Luigi Cavanna Fausto Meriggi Davide Tassinari Claudia Corbo Angela Gernone Veronica Prati Simona Carnio Pasqualina Giordano Angela Maria Dicorato Claudio Verusio Francesco Atzori Francesco Carrozza Stefania Gori Antonino Castro Sara Pilotto Vanja Vaccaro Elisabetta Garzoli Francesco Di Costanzo Evaristo Maiello Roberto Labianca Carmine Pinto Michele Tognetto Sebastiano Buti
container_volume	12
class	RC254-282
format_se	Elektronische Aufsätze
author-letter	Melissa Bersanelli
doi_str_mv	10.1177/1758835920968463
author2-role	verfasserin
title_sort	symptomatic covid-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by ficog
callnumber	RC254-282
title_auth	Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG
abstract	Background: This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from October 2019 to January 2020. The primary endpoint was the incidence of influenza-like illness (ILI) until 30 April 2020. All the ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded. Therefore, the study prospectively recorded all the COVID-19 ILI events. Patients and methods: Patients were included in this non-prespecified COVID-19 analysis, if alive on 31 January 2020, when the Italian government declared the national emergency. The prevalence of confirmed COVID-19 cases was detected as ILI episode with laboratory confirmation of SARS-CoV-2. Cases with clinical-radiological diagnosis of COVID-19 (COVID-like ILIs), were also reported. Results: Out of 1257 enrolled patients, 955 matched the inclusion criteria for this unplanned analysis. From 31 January to 30 April 2020, 66 patients had ILI: 9 of 955 cases were confirmed COVID-19 ILIs, with prevalence of 0.9% [95% confidence interval (CI): 0.3–2.4], a hospitalization rate of 100% and a mortality rate of 77.8%. Including 5 COVID-like ILIs, the overall COVID-19 prevalence was 1.5% (95% CI: 0.5–3.1), with 100% hospitalization and 64% mortality. The presence of elderly, males and comorbidities was significantly higher among patients vaccinated against influenza versus unvaccinated ( p = 0.009, p < 0.0001, p < 0.0001). Overall COVID-19 prevalence was 1.2% for vaccinated (six of 482 cases, all confirmed) and 1.7% for unvaccinated (8 of 473, 3 confirmed COVID-19 and 5 COVID-like), p = 0.52. The difference remained non-significant, considering confirmed COVID-19 only ( p = 0.33). Conclusion: COVID-19 has a meaningful clinical impact on the cancer-patient population receiving ICIs, with high prevalence, hospitalization and an alarming mortality rate among symptomatic cases. Influenza vaccination does not protect from SARS-CoV-2 infection.
abstractGer	Background: This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from October 2019 to January 2020. The primary endpoint was the incidence of influenza-like illness (ILI) until 30 April 2020. All the ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded. Therefore, the study prospectively recorded all the COVID-19 ILI events. Patients and methods: Patients were included in this non-prespecified COVID-19 analysis, if alive on 31 January 2020, when the Italian government declared the national emergency. The prevalence of confirmed COVID-19 cases was detected as ILI episode with laboratory confirmation of SARS-CoV-2. Cases with clinical-radiological diagnosis of COVID-19 (COVID-like ILIs), were also reported. Results: Out of 1257 enrolled patients, 955 matched the inclusion criteria for this unplanned analysis. From 31 January to 30 April 2020, 66 patients had ILI: 9 of 955 cases were confirmed COVID-19 ILIs, with prevalence of 0.9% [95% confidence interval (CI): 0.3–2.4], a hospitalization rate of 100% and a mortality rate of 77.8%. Including 5 COVID-like ILIs, the overall COVID-19 prevalence was 1.5% (95% CI: 0.5–3.1), with 100% hospitalization and 64% mortality. The presence of elderly, males and comorbidities was significantly higher among patients vaccinated against influenza versus unvaccinated ( p = 0.009, p < 0.0001, p < 0.0001). Overall COVID-19 prevalence was 1.2% for vaccinated (six of 482 cases, all confirmed) and 1.7% for unvaccinated (8 of 473, 3 confirmed COVID-19 and 5 COVID-like), p = 0.52. The difference remained non-significant, considering confirmed COVID-19 only ( p = 0.33). Conclusion: COVID-19 has a meaningful clinical impact on the cancer-patient population receiving ICIs, with high prevalence, hospitalization and an alarming mortality rate among symptomatic cases. Influenza vaccination does not protect from SARS-CoV-2 infection.
abstract_unstemmed	Background: This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from October 2019 to January 2020. The primary endpoint was the incidence of influenza-like illness (ILI) until 30 April 2020. All the ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded. Therefore, the study prospectively recorded all the COVID-19 ILI events. Patients and methods: Patients were included in this non-prespecified COVID-19 analysis, if alive on 31 January 2020, when the Italian government declared the national emergency. The prevalence of confirmed COVID-19 cases was detected as ILI episode with laboratory confirmation of SARS-CoV-2. Cases with clinical-radiological diagnosis of COVID-19 (COVID-like ILIs), were also reported. Results: Out of 1257 enrolled patients, 955 matched the inclusion criteria for this unplanned analysis. From 31 January to 30 April 2020, 66 patients had ILI: 9 of 955 cases were confirmed COVID-19 ILIs, with prevalence of 0.9% [95% confidence interval (CI): 0.3–2.4], a hospitalization rate of 100% and a mortality rate of 77.8%. Including 5 COVID-like ILIs, the overall COVID-19 prevalence was 1.5% (95% CI: 0.5–3.1), with 100% hospitalization and 64% mortality. The presence of elderly, males and comorbidities was significantly higher among patients vaccinated against influenza versus unvaccinated ( p = 0.009, p < 0.0001, p < 0.0001). Overall COVID-19 prevalence was 1.2% for vaccinated (six of 482 cases, all confirmed) and 1.7% for unvaccinated (8 of 473, 3 confirmed COVID-19 and 5 COVID-like), p = 0.52. The difference remained non-significant, considering confirmed COVID-19 only ( p = 0.33). Conclusion: COVID-19 has a meaningful clinical impact on the cancer-patient population receiving ICIs, with high prevalence, hospitalization and an alarming mortality rate among symptomatic cases. Influenza vaccination does not protect from SARS-CoV-2 infection.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_121 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_374 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2704 GBV_ILN_2707 GBV_ILN_2889 GBV_ILN_2890 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
title_short	Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG
url	https://doi.org/10.1177/1758835920968463 https://doaj.org/article/56f65524e4484c51b38e78016965cac1 https://doaj.org/toc/1758-8359
remote_bool	true
author2	Diana Giannarelli Ugo De Giorgi Sandro Pignata Massimo Di Maio Elena Verzoni Alberto Clemente Valentina Guadalupi Diego Signorelli Marcello Tiseo Raffaele Giusti Marco Filetti Marilena Di Napoli Lorenzo Calvetti Alessandro Cappetta Paola Ermacora Diego Zara Fausto Barbieri Cinzia Baldessari Vieri Scotti Francesca Mazzoni Antonello Veccia Pamela Francesca Guglielmini Marco Maruzzo Ernesto Rossi Francesco Grossi Chiara Casadei Alessio Cortellini Francesco Verderame Vincenzo Montesarchio Mimma Rizzo Manlio Mencoboni Fable Zustovich Lucia Fratino Saverio Cinieri Giorgia Negrini Maria Banzi Mariella Sorarù Paolo Andrea Zucali Gaetano Lacidogna Antonio Russo Nicola Battelli Giuseppe Fornarini Claudia Mucciarini Sergio Bracarda Andrea Bonetti Debora Pezzuolo Lucia Longo Donata Sartori Mauro Iannopollo Luigi Cavanna Fausto Meriggi Davide Tassinari Claudia Corbo Angela Gernone Veronica Prati Simona Carnio Pasqualina Giordano Angela Maria Dicorato Claudio Verusio Francesco Atzori Francesco Carrozza Stefania Gori Antonino Castro Sara Pilotto Vanja Vaccaro Elisabetta Garzoli Francesco Di Costanzo Evaristo Maiello Roberto Labianca Carmine Pinto Michele Tognetto Sebastiano Buti
author2Str	Diana Giannarelli Ugo De Giorgi Sandro Pignata Massimo Di Maio Elena Verzoni Alberto Clemente Valentina Guadalupi Diego Signorelli Marcello Tiseo Raffaele Giusti Marco Filetti Marilena Di Napoli Lorenzo Calvetti Alessandro Cappetta Paola Ermacora Diego Zara Fausto Barbieri Cinzia Baldessari Vieri Scotti Francesca Mazzoni Antonello Veccia Pamela Francesca Guglielmini Marco Maruzzo Ernesto Rossi Francesco Grossi Chiara Casadei Alessio Cortellini Francesco Verderame Vincenzo Montesarchio Mimma Rizzo Manlio Mencoboni Fable Zustovich Lucia Fratino Saverio Cinieri Giorgia Negrini Maria Banzi Mariella Sorarù Paolo Andrea Zucali Gaetano Lacidogna Antonio Russo Nicola Battelli Giuseppe Fornarini Claudia Mucciarini Sergio Bracarda Andrea Bonetti Debora Pezzuolo Lucia Longo Donata Sartori Mauro Iannopollo Luigi Cavanna Fausto Meriggi Davide Tassinari Claudia Corbo Angela Gernone Veronica Prati Simona Carnio Pasqualina Giordano Angela Maria Dicorato Claudio Verusio Francesco Atzori Francesco Carrozza Stefania Gori Antonino Castro Sara Pilotto Vanja Vaccaro Elisabetta Garzoli Francesco Di Costanzo Evaristo Maiello Roberto Labianca Carmine Pinto Michele Tognetto Sebastiano Buti
ppnlink	604082282
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1177/1758835920968463
callnumber-a	RC254-282
up_date	2024-07-03T16:39:45.987Z
_version_	1803576709995298817
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ048233021</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308133408.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1177/1758835920968463</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ048233021</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ56f65524e4484c51b38e78016965cac1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Melissa Bersanelli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from October 2019 to January 2020. The primary endpoint was the incidence of influenza-like illness (ILI) until 30 April 2020. All the ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded. Therefore, the study prospectively recorded all the COVID-19 ILI events. Patients and methods: Patients were included in this non-prespecified COVID-19 analysis, if alive on 31 January 2020, when the Italian government declared the national emergency. The prevalence of confirmed COVID-19 cases was detected as ILI episode with laboratory confirmation of SARS-CoV-2. Cases with clinical-radiological diagnosis of COVID-19 (COVID-like ILIs), were also reported. Results: Out of 1257 enrolled patients, 955 matched the inclusion criteria for this unplanned analysis. From 31 January to 30 April 2020, 66 patients had ILI: 9 of 955 cases were confirmed COVID-19 ILIs, with prevalence of 0.9% [95% confidence interval (CI): 0.3–2.4], a hospitalization rate of 100% and a mortality rate of 77.8%. Including 5 COVID-like ILIs, the overall COVID-19 prevalence was 1.5% (95% CI: 0.5–3.1), with 100% hospitalization and 64% mortality. The presence of elderly, males and comorbidities was significantly higher among patients vaccinated against influenza versus unvaccinated ( p = 0.009, p < 0.0001, p < 0.0001). Overall COVID-19 prevalence was 1.2% for vaccinated (six of 482 cases, all confirmed) and 1.7% for unvaccinated (8 of 473, 3 confirmed COVID-19 and 5 COVID-like), p = 0.52. The difference remained non-significant, considering confirmed COVID-19 only ( p = 0.33). Conclusion: COVID-19 has a meaningful clinical impact on the cancer-patient population receiving ICIs, with high prevalence, hospitalization and an alarming mortality rate among symptomatic cases. Influenza vaccination does not protect from SARS-CoV-2 infection.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Diana Giannarelli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ugo De Giorgi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sandro Pignata</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Massimo Di Maio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Elena Verzoni</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alberto Clemente</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Valentina Guadalupi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Diego Signorelli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marcello Tiseo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Raffaele Giusti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marco Filetti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marilena Di Napoli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lorenzo Calvetti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alessandro Cappetta</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paola Ermacora</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Diego Zara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fausto Barbieri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cinzia Baldessari</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vieri Scotti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francesca Mazzoni</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Antonello Veccia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pamela Francesca Guglielmini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marco Maruzzo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ernesto Rossi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francesco Grossi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chiara Casadei</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alessio Cortellini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francesco Verderame</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vincenzo Montesarchio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mimma Rizzo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Manlio Mencoboni</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fable Zustovich</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lucia Fratino</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Saverio Cinieri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giorgia Negrini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maria Banzi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mariella Sorarù</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paolo Andrea Zucali</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gaetano Lacidogna</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Antonio Russo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicola Battelli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giuseppe Fornarini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Claudia Mucciarini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sergio Bracarda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrea Bonetti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Debora Pezzuolo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lucia Longo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Donata Sartori</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mauro Iannopollo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luigi Cavanna</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fausto Meriggi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Davide Tassinari</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Claudia Corbo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Angela Gernone</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Veronica Prati</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Simona Carnio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pasqualina Giordano</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Angela Maria Dicorato</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Claudio Verusio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francesco Atzori</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francesco Carrozza</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stefania Gori</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Antonino Castro</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sara Pilotto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vanja Vaccaro</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Elisabetta Garzoli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francesco Di Costanzo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Evaristo Maiello</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Roberto Labianca</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Carmine Pinto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Michele Tognetto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sebastiano Buti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Therapeutic Advances in Medical Oncology</subfield><subfield code="d">SAGE Publishing, 2018</subfield><subfield code="g">12(2020)</subfield><subfield code="w">(DE-627)604082282</subfield><subfield code="w">(DE-600)2503443-1</subfield><subfield code="x">17588359</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2020</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1177/1758835920968463</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/56f65524e4484c51b38e78016965cac1</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1177/1758835920968463</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1758-8359</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_121</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_374</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2704</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2707</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2889</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2890</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2020</subfield></datafield></record></collection>
score	7.3993254

Nicht das Richtige dabei?

Schreiben Sie uns!

Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?